Related references
Note: Only part of the references are listed.Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J. Motzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
Cinzia Solinas et al.
ESMO OPEN (2020)
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Francisco J. Esteva et al.
LANCET ONCOLOGY (2019)
Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
Anna Wilkins et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab
Thilo Gambichler et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The appropriate frequency and function of decidual Tim-3+CTLA-4+CD8+ T cells are important in maintaining normal pregnancy
Songcun Wang et al.
CELL DEATH & DISEASE (2019)
CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro
Sandra Rosskopf et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis
Yuhan Wei et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Immune-Related Adverse Events: A Case-Based Approach
Caoilfhionn Connolly et al.
FRONTIERS IN ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer
Cinzia Solinas et al.
CANCERS (2019)
Targeting PD-1 in cancer: Biological insights with a focus on breast cancer
Cinzia Solinas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Significance of TIM3 expression in cancer: From biology to the clinic
Cinzia Solinas et al.
SEMINARS IN ONCOLOGY (2019)
Immune mechanisms mediating abscopal effects in radioimmunotherapy
Maria E. Rodriguez-Ruiz et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
Ruben S. A. Goedegebuure et al.
FRONTIERS IN IMMUNOLOGY (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair et al.
FRONTIERS IN IMMUNOLOGY (2019)
Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors
Franziska Eckert et al.
FRONTIERS IN IMMUNOLOGY (2019)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer
Gregory Noel et al.
SEMINARS IN CANCER BIOLOGY (2018)
The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?
Zuzana Hlavata et al.
TARGETED ONCOLOGY (2018)
Combination of radiotherapy and immune treatment: First clinical data
D. De Ruysscher
CANCER RADIOTHERAPIE (2018)
The hallmarks of successful anticancer immunotherapy
Lorenzo Galluzzi et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Not All Immune Checkpoints Are Created Equal
Annika De Sousa Linhares et al.
FRONTIERS IN IMMUNOLOGY (2018)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies (vol 33, pg 581, 2018)
Roberta Zappasodi et al.
CANCER CELL (2018)
Nobel committee honors tumor immunologists
Anand Rotte et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
Yang Liu et al.
TRENDS IN IMMUNOLOGY (2018)
CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
Monika C. Brunner-Weinzierl et al.
FRONTIERS IN IMMUNOLOGY (2018)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy
Cinzia Solinas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (CheckMate 067)
James Larkin et al.
CANCER RESEARCH (2017)
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Chunyan Gu-Trantien et al.
JCI INSIGHT (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Sumit K. Subudhi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Affinity and dose of TCR engagement yield proportional enhancer and gene activity in CD4+T cells
Karmel A. Allison et al.
ELIFE (2016)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Confusing signals: Recent progress in CTLA-4 biology
Lucy S. K. Walker et al.
TRENDS IN IMMUNOLOGY (2015)
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
Luana Calabro et al.
LANCET RESPIRATORY MEDICINE (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
David McDermott et al.
CANCER TREATMENT REVIEWS (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Metabolic Regulation of T Lymphocytes
Nancie J. MacIver et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabro et al.
LANCET ONCOLOGY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Human Prostate Tumor Antigen-Specific CD8+ Regulatory T Cells Are Inhibited by CTLA-4 or IL-35 Blockade
Brian M. Olson et al.
JOURNAL OF IMMUNOLOGY (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Human plasmacytoid dendritic cells induce CD8+ LAG-3+Foxp3+CTLA-4+ regulatory T cells that suppress allo-reactive memory T cells
Patrick P. C. Boor et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults
Jaikumar Duraiswamy et al.
JOURNAL OF IMMUNOLOGY (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions
Stefania Laurent et al.
HUMAN IMMUNOLOGY (2010)
Spatiotemporal Basis of CTLA-4 Costimulatory Molecule-Mediated Negative Regulation of T Cell Activation
Tadashi Yokosuka et al.
IMMUNITY (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Brian Kavanagh et al.
BLOOD (2008)
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
Brian T. Fife et al.
IMMUNOLOGICAL REVIEWS (2008)
Glucose uptake is limiting in T cell activation and requires CD28-mediated akt-dependent and independent pathways
Sarah R. Jacobs et al.
JOURNAL OF IMMUNOLOGY (2008)
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
Chrysoula I. Liakou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo
Simon Read et al.
JOURNAL OF IMMUNOLOGY (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
HC Probst et al.
NATURE IMMUNOLOGY (2005)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
The CD28 signaling pathway regulates glucose metabolism
KA Frauwirth et al.
IMMUNITY (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
